Tscan Therapeutics, Inc. last reported quarterly results on Aug 12, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): revenue of $1.1 million (-65.8% year over year) and diluted EPS of -$0.23. It usually reports 36–63 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 11, 2026.
Results for Q3 FY2026, the quarter ending around Sep 30, 2026. Expected on a Wednesday. Based on last year's release for the same quarter on Nov 12, 2025. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 36–63 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Aug 12, 2026
43 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
1
-65.8%
|
-30
+17.8%
|
-0.23
+17.9%
|
|
May 6, 2026
36 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
1
-54.8%
|
-29
+16.0%
|
-0.22
+15.4%
|
|
Mar 4, 2026
63 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
3
+286.0%
|
-23
+35.8%
|
-0.18
+40.3%
|
|
Nov 12, 2025
43 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
3
+139.4%
|
-36
-19.5%
|
-0.28
-12.0%
|
|
Aug 12, 2025
43 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
3
+473.9%
|
-37
-16.7%
|
-0.28
+0.0%
|
|
May 6, 2025
36 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
2
+283.6%
|
-34
-13.2%
|
-0.26
+18.8%
|
|
Mar 5, 2025
64 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
1
-90.8%
|
-36
-82.6%
|
-0.30
-43.4%
|
|
Nov 12, 2024
43 days after quarter end
|
Q3 FY2024
ended Sep 30, 2024
|
1
-73.0%
|
-30
-30.0%
|
-0.25
-4.2%
|
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- TCRX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Waltham, MA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1783328
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.